Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical, biotechnology, agrochemical, cosmetics and food industries, today announced the entry into an underwriting agreement relating to the sale of 1,818,182 shares of its common stock at an offering price of $55.00 per share, less underwriting discounts and commission. The offering is expected to close on or about August 10, 2020, subject to satisfaction of customary closing conditions. Simulations Plus has granted the underwriters a 30-day option to purchase up to 272,727 additional shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any.

Oppenheimer & Co. Inc. and Raymond James & Associates, Inc. are acting as joint book-running managers for the offering. Craig-Hallum Capital Group is acting as co-manager for the offering.

The gross proceeds from the offering are expected to be $100 million, before deducting underwriting discounts and commissions and estimated offering expenses.

Simulations Plus intends to use the net proceeds from the offering for strategic mergers and acquisitions, although Simulations Plus has no present commitments or agreements to enter into any such mergers or acquisitions, working capital requirements and other general corporate purposes, including investing in enhanced information and accounting systems, and personnel in support of corporate growth.

This offering is being made pursuant to an automatic shelf registration statement on Form S-3 (No. 333-239770), which was previously filed with the Securities and Exchange Commission (“SEC”) on July 9, 2020, which became automatically effective. The preliminary prospectus supplement related to this offering was filed with the SEC on August 4, 2020. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC’s website located at https://www.sec.gov, or by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com; or Raymond James & Associates, Inc., Attention: Syndicate Department, 880 Carillon Parkway, St. Petersburg, FL 33716, by telephone at (800) 248-8863 or by email at prospectus@raymondjames.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.